The DOI matches its Crossref record; 365 of the 366 references it cites were found in a registry or an index.
Digging deep into “dirty” drugs – modulation of the methylation machinery
Open accessAbstract
DNA methylation and histone modification are epigenetic mechanisms that result in altered gene expression and cellular phenotype. The exact role of methylation in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) remains unclear. However, aberrations (e.g. loss-/gain-of-function or up-/down-regulation) in components of epigenetic transcriptional regulation in general, and of the methylation machinery in particular, have been implicated in the pathogenesis of these diseases. In addition, many of these components have been identified as therapeutic targets for patients with MDS/AML, and are also being assessed as potential biomarkers of response or resistance to hypomethylating agents (HMAs). The HMAs 5-azacitidine (AZA) and 2'-deoxy-5-azacitidine (decitabine, DAC) inhibit DNA methylation and have shown significant clinical benefits in patients with myeloid malignancies. Despite being viewed as mechanistically similar drugs, AZA and DAC have differing mechanisms of action. DAC is incorporated 100% into DNA, whereas AZA is incorporated into RNA (80-90%) as well as DNA (10-20%). As such, both drugs inhibit DNA methyltransferases (DNMTs; dependently or independently of DNA replication) resulting in the re-expression of tumor-suppressor genes; however, AZA also has an impact on mRNA and protein metabolism via its inhibition of ribonucleotide reductase, resulting in apoptosis. Herein, we first give an overview of transcriptional regulation, including DNA methylation, post-translational histone-tail modifications, the role of micro-RNA and long-range epigenetic gene silencing. We place special emphasis on epigenetic transcriptional regulation and discuss the implication of various components in the pathogenesis of MDS/AML, their potential as therapeutic targets, and their therapeutic modulation by HMAs and other substances (if known). The main focus of this review is laid on dissecting the rapidly evolving knowledge of AZA and DAC with a special focus on their differing mechanisms of action, and the effect of HMAs on transcriptional regulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prolonged time to initial response, which typically occurs around 3 months from treatment onset 125 , is consistent with the primary effects of low dose treatment being mediated via DNA demethylation and epigenetic reprogramming as opposed to direct cytotoxicity 126-128 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Ghoshal, K., Datta, J., Majumder, S., Bai, S., Kutay, H., Motiwala, T., & Jacob, S. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.11.4727-4741.2005 · Cited by 444 · cited 12×
“Ghoshal et al. (2005) 3 Only minor substitution of 5-azacytosine for cytosine in DNA (approximately 0.3”
BackgroundInfluentialRetractedHerrera-Merchan, A., Arranz, L., Ligos, J. M., de Molina-Iracheta, A., Domı́nguez, O., & González, S. (2012) · Nature Communications · doi:10.1038/ncomms1623 · Cited by 121 · cited 1×
“In contrast, ectopic expression of EZH2 seems to result in myeloid transformation (Herrera-Merchan et al., 2012).”
BackgroundRetractedHerrera-Merchan, A., Arranz, L., Ligos, J. M., de Molina-Iracheta, A., Domı́nguez, O., & González, S. (2017) · Nature Communications · doi:10.1038/ncomms14005 · Cited by 108
RetractedA microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia
Yin, B., Tsai, M., Hasz, D. E., Rathe, S. K., Beau, M. M. L., & Largaespada, D. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404595 · Cited by 14 · cited 1×
“Furthermore, mutations in, and/or altered expression levels of nucleoside metabolizing enzymes, have been correlated with resistance to Ara-C and have been proposed as potential prognostic markers of response (Galmarini et al., 2001; Rathe & Largaespada, 2010; Yin et al., 2007).”
BackgroundRetractedCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466 · cited 1×
“Histone octamers consist of eight proteins, consisting of two copies of each of the core histones H2A, H2B, H3 and H4 (Luger et al., 1997).”
BackgroundShrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325 · cited 2×
“Keywords Acute myeloid leukemia, azacitidine, decitabine, DNA methylation, epigenetics, hypomethylating agents, myelodysplastic syndrome, transcriptional regulation History Received 12 October 2014 Revised 26 November 2014 Accepted 1 December 2014 Published online 8 January 2015”
BackgroundOkano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143 · cited 2×
“DNMT3A and 3B exhibit predominant denovo methyltransferase activity, initiating DNA methylation marks on unmethylated DNA (Okano et al., 1999) (Figure 2A and C), whereas DNMT1 is exclusively involved in the The green field demarks methylation, whereas the red field demarks occurring demethylation.”
BackgroundConversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · cited 2×
“TET proteins can also drive the 5-mC oxidation process further to produce 5formylcytosine (5-fC) and 5-carboxylcytosine (5-caC) as reaction products (Pfeifer et al., 2014; Tahiliani et al., 2009) (Figures 1A-V, 1A-VI, 2B and D).”
BackgroundCancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Research works printed but not linked: 10
- Chabot GG, 1983, Cancer Res, 43, 592
- Cihak A, 1974, Cancer Res, 34, 3003
- Curt GA, 1985, Cancer Res, 45, 3359
- Glover AB, 1987, Cancer Treat Rep, 71, 959
- Jones PA, 1983, Recent Results Cancer Res, 84, 202
- Li LH, 1970, Cancer Res, 30, 2760
- Lin X, 2014, Clin Transl Oncol
- Lu LJ, 1980, Cancer Res, 40, 2701
- Marce S, 2006, Haematologica, 91, 895
- van Groeningen CJ, 1986, Cancer Res, 46, 4831
Cited by
Sorted by citations
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377
Camicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 177
“(DAC/5-AZA) inhibit DNA methyltransferases (mainly DMNT1 and DMNT3) resulting in the re-expression of tumor-suppressor genes [419, 420].”
BackgroundThe emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145
Döhner, H., Dolnik, A., Tang, L., Seymour, J. F., Minden, M. D., Stone, R. M., Bernal, T., Al‐Ali, H. K., Santini, V., Vyas, P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0257-z · Cited by 132
Metadata
- Authors
- Pleyer, L., & Greil, R.
- Affiliations
- Paracelsus Medical University (AT)
- Corresponding author
- Pleyer, Lisa
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2015-01-08
- Volume
- 47
- Issue
- 2
- Pages
- 252-279
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- PMC
- PMC4733942
- OpenAlex
- W1992220938
- Cited by
- 84
- References
- 366
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 13 · 2020: 7 · 2019: 11 · 2018: 9 · 2017: 8 · 2016: 7 · 2015: 3
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Drug Metabolism Reviews (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- DNA methylation, histone modifications, myelodysplastic syndrome, acute myeloid leukemia, hypomethylating agents, azacitidine, decitabine, DNA methyltransferases, ribonucleotide reductase, microRNA, therapeutic target
- MeSH terms
- Decitabine, Animals, Antimetabolites, Antineoplastic, Azacitidine, Clinical Trials as Topic, Humans, Myelodysplastic Syndromes, Transcription, Genetic, Leukemia, Myeloid, Acute, DNA Methylation, Histone Code, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
